Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis | Otolaryngology | JAMA

This systematic review and dose-response meta-analysis evaluates the efficacy and tolerability of gefapixant, a new P2X3 antagonist, for the treatment of adults

Related Keywords

United States ,Switzerland ,Milan ,Lombardia ,Italy ,Japan ,Canada ,Canadian ,American ,Ej Moran Campbell ,Cochrane Ro , ,European Respiratory Society ,European Medicines Agency ,Department Of Medicine ,Bellus Health ,Cochrane Bias Methods Group ,Faculty Of Health Sciences ,American Academy Of Allergy ,Mcmaster University Medical Centre ,Canadian Lung Association ,Mcmaster University ,Genentech ,Canadian Institutes Of Health Research ,American College Of Chest Physicians ,Glaxosmithkline ,Drug Administration ,R Foundation For Statistical Computing ,Novartis ,Health Canada ,International Congress ,Astrazeneca ,Immunology Foundation ,Faculty Development Award ,Leicester Cough Questionnaire ,Cochrane Central Register ,Controlled Trials ,Preferred Reporting Items ,Systematic Reviews ,Cough Quality Of Life Questionnaire ,Bias Assessments ,Cochrane Rob ,Statistical Computing ,Included Studies ,Hour Cough Frequency ,Cough Frequency ,Specific Quality ,Related Adverse Events ,Events Leading ,American College ,European Respiratory ,Imran Satia ,Health Sciences ,Interest Disclosures ,Canadian Institutes ,Health Research ,Canada Graduate Scholarships Doctoral Award ,Fellowship Award ,Canadian Asthma ,American Academy ,Moran Campbell Early Career Award ,